← All patents

US9399662B2

Concurrent chemotherapy and immunotherapy

University of Texas System

Abstract

The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
John H. Sampson
Priority date
November 02, 2005
Filing date
November 02, 2006
Grant date
July 26, 2016
Publication date
July 26, 2016
Language
en
Metadata fetched
August 29, 2026 00:24